\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ visual\\ field\\ defect\\.\ \(0\)\
\-\ papilledema\\.\ \(8\)\
\-\ surgical\\ drainage\\ of\\ cystic\\ portion\\ of\\ tumor\\.\\ \\ radiation\\ therapy\\ pending\\ for\\ residual\\/remaining\\ tumor\\.\ \(0\)\
\-\ calcified\\,\\ cystic\\ mass\\ in\\ the\\ sella\\ and\\ supra\\ sellar\\ cistern\\.\\ \\ lower\\ calcified\\ sellar\\ portion\\ of\\ mass\\ enhances\\ in\\-homogeneously\\ and\\ the\\ cysts\\ enhance\\ in\\ a\\ ring\\-like\\ fashion\\.\ \(0\)\
\-\ craniopharyngioma\ \(24\)\
\-\ \\â\\€\\¢\\ meningioma\ \(7\)\
\-\ \\â\\€\\¢\\ dermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\ cystic\\ pituitary\\ adenoma\ \(0\)\
\-\ \\â\\€\\¢\\ craniopharyngioma\ \(0\)\
\-\ \\â\\€\\¢\\ epidermoid\\ cyst\ \(0\)\
\-\ \\â\\€\\¢\\ hypothalamic\\ glioma\ \(0\)\
\-\ 22\\ year\\ old\\ woman\\ who\\ presents\\ with\\ a\\ first\\ time\\ seizure\\.\ \(1\)\
\-\ previous\\ history\\ of\\ a\\ \\"mood\\ disorder\\"\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ sellar\\:\\ 0\\.14473185179938783\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.10446762343972586\ \(0\)\
\-\ craniopharyngioma\\:\\ 0\\.10055686628484684\ \(0\)\
\-\ residual\\/remaining\\:\\ 0\\.09795020471073887\ \(0\)\
\-\ in\\-homogeneously\\:\\ 0\\.09795020471073887\ \(0\)\
\-\ cystic\\:\\ 0\\.08215442357505862\ \(0\)\
\-\ calcified\\:\\ 0\\.08151164327006767\ \(0\)\
\-\ mood\\:\\ 0\\.07804176616376048\ \(0\)\
\-\ supra\\:\\ 0\\.0763289808323465\ \(0\)\
\-\ ring\\-like\\:\\ 0\\.07353659829589199\ \(0\)\
\-\ portion\\:\\ 0\\.06878236994131304\ \(0\)\
\-\ fashion\\:\\ 0\\.06263849548465059\ \(0\)\
\-\ hypothalamic\\:\\ 0\\.06263849548465059\ \(0\)\
\-\ papilledema\\:\\ 0\\.05910012069444464\ \(0\)\
\-\ sella\\:\\ 0\\.05470775695395413\ \(0\)\
\-\ cyst\\:\\ 0\\.05103046968946895\ \(0\)\
\-\ cistern\\:\\ 0\\.050744702021301547\ \(0\)\
\-\ field\\:\\ 0\\.048718906945813156\ \(0\)\
\-\ pituitary\\:\\ 0\\.04758798812014713\ \(0\)\
\-\ enhance\\:\\ 0\\.04592652440935865\ \(0\)\
\-\ epidermoid\\:\\ 0\\.04522873661781387\ \(0\)\
\-\ enhances\\:\\ 0\\.04484883256505521\ \(0\)\
\-\ tumor\\:\\ 0\\.044271828924684696\ \(0\)\
\-\ dermoid\\:\\ 0\\.04328374997931526\ \(0\)\
\-\ visual\\:\\ 0\\.0430430666817466\ \(0\)\
\-\ glioma\\:\\ 0\\.0428074865967399\ \(0\)\
\-\ disorder\\:\\ 0\\.04265316312828804\ \(0\)\
\-\ 22\\:\\ 0\\.04235080131134488\ \(0\)\
\-\ seizure\\:\\ 0\\.04198406468392077\ \(0\)\
\-\ pending\\:\\ 0\\.041083606794997146\ \(0\)\
\-\ drainage\\:\\ 0\\.03970857121007618\ \(0\)\
\-\ adenoma\\:\\ 0\\.039649937242289025\ \(0\)\
\-\ cysts\\:\\ 0\\.03719398092034852\ \(0\)\
\-\ previous\\:\\ 0\\.036870557763036625\ \(0\)\
\-\ meningioma\\:\\ 0\\.03651210373838972\ \(0\)\
\-\ defect\\:\\ 0\\.035541636958888075\ \(0\)\
\-\ first\\:\\ 0\\.031860927053176134\ \(0\)\
\-\ radiation\\:\\ 0\\.031158347217359293\ \(0\)\
\-\ time\\:\\ 0\\.02681779141377014\ \(0\)\
\-\ mass\\:\\ 0\\.02641024459883477\ \(0\)\
\-\ therapy\\:\\ 0\\.02538489773600681\ \(0\)\
\-\ who\\:\\ 0\\.024755204546018914\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.023334833751464636\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.022886105577580477\ \(0\)\
\-\ woman\\:\\ 0\\.02193225497209896\ \(0\)\
\-\ lower\\:\\ 0\\.021354022992931807\ \(0\)\
\-\ surgical\\:\\ 0\\.019958019669460595\ \(0\)\
\-\ presents\\:\\ 0\\.019396047727865844\ \(0\)\
\-\ a\\:\\ 0\\.013219993393953376\ \(0\)\
\-\ history\\:\\ 0\\.013113494863412038\ \(0\)\
\-\ year\\:\\ 0\\.010623391880810164\ \(0\)\
\-\ old\\:\\ 0\\.009721495520691719\ \(0\)\
\-\ no\\:\\ 0\\.009560490563375578\ \(0\)\
\-\ in\\:\\ 0\\.009364382892005665\ \(0\)\
\-\ for\\:\\ 0\\.008101201651585723\ \(0\)\
\-\ of\\:\\ 0\\.005177946702132819\ \(0\)\
\-\ and\\:\\ 0\\.004000200127382633\ \(0\)\
\-\ \\.\\:\\ 0\\.0031555143197641135\ \(0\)\
\-\ the\\:\\ 0\\.00307220632674724\ \(0\)\
\-\ \\,\\:\\ 0\\.0030078896168587487\ \(0\)\
\-\ with\\:\\ 0\\.001300046400998775\ \(0\)\
